Galen in pact with US rival to end patent wrangles
Friday 12 September 2003
Galen, the women's healthcare group, has tied up a wide-ranging and innovative deal with its US rival, Barr Laboratories, that ends most patent litigation between the pair and fends off copycat competition to several of its important drugs.
Galen shares jumped 8 per cent to 657.5p on the news, which analysts said removed a number of the competition fears that have dogged the stock this year.
Barr, which attempted to buy Galen earlier this year, is paying $45m (£28m) to acquire one off-patent contraceptive and the right to sell generic versions of two hormone replacement therapies shortly before their patents expire later this decade.
The deal settles patent litigation between the two companies over the HRT treatments Estrostep and femhrt, protecting Galen's exclusivity - and, hence, its high margins - over the products until 2007 and 2009 respectively.
There is also an innovative deal on Ovcon, Galen's most important contraceptive pill. Barr has lined up a cut-price copy of the drug, but Galen has bought an option to sell it on Barr's behalf. This would ensure the price is not eroded at least until Galen is able to launch an improved, patent-protected version of the drug.
Both companies have received advice from their lawyers that the deal will not fall foul of competition authorities in the US, who have previously shown themselves ready to use anti-trust laws to hasten the switch from branded drugs to cheaper copies.
Loestrin, the contraceptive pill that is being sold to Barr, was not being actively marketed by Galen, according to the chairman, John King. Loestrin, which was acquired from Pfizer this year, already faces generic competition and had sales of $16.7m (£10.5m) in the last three months.
Dr King said: "This deal has removed three of the risk factors that have been hanging over us. We have always taken a robust attitude to patent rights and we are confident in our ability to defend other patents."
There is still one outstanding issue between Barr and Galen, over the patents for Sarafem, a treatment for severe menstrual tension which Galen bought last year and whose patents are being challenged by Barr. The two are scheduled to clash in a US court in November.
Galen has repeatedly been criticised for providing only limited information on the existence and progress of its patent disputes.
- 1 VMAs 2015: Was Nicki Minaj and Miley Cyrus' awkward acceptance put-down real or staged?
- 2 If you're not already angry about the migrant crisis, here's a history lesson to remind you why you really should be
- 3 Rules on 5p plastic bags likely to lead to arguments at the check-out
- 4 Chaos breaks out in courtroom as father attacks killer of three-year-old daughter
- 5 I like Corbyn, but let's face it: we don't need another white man at the head of a political party
VMAs 2015: Was Nicki Minaj and Miley Cyrus' awkward acceptance put-down real or staged?
Bank Holiday Monday opening times: Are Tesco, Asda and other supermarkets open today?
Rules on 5p plastic bags likely to lead to arguments at the check-out
The nine most warmongering countries in the world revealed
Isis releases graphic video showing four Shia 'spies' being burned alive in Anbar, Iraq
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Jeremy Corbyn calls Osama bin Laden's killing a 'tragedy' - but was it taken out of context?
Black holes are a passage to another universe, says Stephen Hawking
Tony Blair attacks Jeremy Corbyn's 'Alice In Wonderland' politics
Theresa May says migrants should be banned from entering the UK unless they have jobs lined up
iJobs Money & Business
£25000 - £30000 per annum: Recruitment Genius: From modest beginnings the comp...
£35000 - £40000 per annum: Recruitment Genius: From modest beginnings the comp...
£15000 - £65000 per annum: Recruitment Genius: This is an exciting opportunity...
£18000 - £20000 per annum: Recruitment Genius: This is a fantastic opportunity...